Thyroid Unit, Cancer Center and Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Endocr Pract. 2011 Sep-Oct;17(5):768-87. doi: 10.4158/EP10407.RA.
To review the relevant literature concerning follicular variant of papillary thyroid carcinoma (FVPTC) with an emphasis on the heterogeneity of this disorder and to propose a new classification for FVPTC on the basis of molecular diagnostics and apply the classification to a typical case.
English-language articles pertaining to FVPTC published between January 1990 and December 2010 were reviewed.
FVPTC is particularly vexing. The criteria for diagnosing FVPTC appear to have changed over the years. Pathologists often disagree about the diagnosis of FVPTC. The clinical behavior of these tumors is variable. Molecular diagnostic studies suggest that FVPTC represents a heterogeneous group of disorders rather than a single entity.
On the basis of the available data, it is proposed that individual cases of FVPTC be reclassified as papillary thyroid carcinoma, follicular thyroid carcinoma, or follicular adenomas, after appropriate molecular biologic studies have been completed. Long-term follow-up studies to validate this classification are necessary.
回顾有关滤泡型甲状腺乳头状癌（FVPTC）的相关文献，重点介绍该疾病的异质性，并基于分子诊断提出 FVPTC 的新分类，并将该分类应用于一个典型病例。
回顾了 1990 年 1 月至 2010 年 12 月期间发表的有关 FVPTC 的英文文献。
FVPTC 特别令人困扰。诊断 FVPTC 的标准似乎多年来发生了变化。病理学家对 FVPTC 的诊断常常存在分歧。这些肿瘤的临床行为具有变异性。分子诊断研究表明，FVPTC 代表一组异质性疾病，而不是单一实体。
根据现有数据，建议在完成适当的分子生物学研究后，将个别 FVPTC 病例重新分类为甲状腺乳头状癌、滤泡性甲状腺癌或滤泡性腺瘤。需要进行长期随访研究来验证该分类。
